Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenton Zavitz

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Clinical Cardiology|February 17, 2017
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trialRobert P Giugliano, Francois Mach, Kenton Zavitz, et al.
NEJM Evidence|December 24, 2024
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with EvolocumabAndré Zimerman, Michelle L O'Donoghue, Xinhui Ran, et al.
The New England Journal of Medicine|August 17, 2017
Cognitive Function in a Randomized Trial of EvolocumabRobert P Giugliano, François Mach, Kenton Zavitz, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Clinical Cardiology|February 17, 2017
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trialRobert P Giugliano, Francois Mach, Kenton Zavitz, et al.
NEJM Evidence|December 24, 2024
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with EvolocumabAndré Zimerman, Michelle L O'Donoghue, Xinhui Ran, et al.
The New England Journal of Medicine|August 17, 2017
Cognitive Function in a Randomized Trial of EvolocumabRobert P Giugliano, François Mach, Kenton Zavitz, et al.
Pageof 1